Protocol Section List

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Report Bug
Protocol Section List
You are on Page 736 of 740:
726 727 728 729 730 731 732 733 734 735 736 737 738 739 740

Protocol Sections: The Identification Through IPD Sharing Statement are Modules For This Protocol Section

NCTID Brief Title Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Oversight Description Conditions View
NCT00004367 Vestibular Dysfunction In Adult Patients With Panic Disorder With or Without Agoraphobia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004366 Pilot Study of Vestibular Rehabilitation Training for Panic Disorder With Vestibular Dysfunction Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004361 Study of the Relationship Between Calcium Levels and Intact Parathyroid Hormone (iPTH) in Adults With Repaired or Palliated Conotruncal Cardiac Defects Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004360 Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004359 Phase II Pilot Study of Extracorporeal Phototherapy for Epidermolysis Bullosa Acquisita Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004358 Phase II Study of Calcitonin for Tumoral Calcinosis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004357 Absorption of Corticosteroids in Children With Juvenile Dermatomyositis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004356 Study of Homocysteine Metabolism in Homocystinuria Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004351 Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004350 Evaluation of Fanconi Syndrome and Cystinosis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004335 Study of Gonadotropin-Releasing Hormone Pulse Frequency in Sexual Maturation and in the Menstrual Cycle Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004334 Study of Depression, Peptides, and Steroids in Cushing's Syndrome Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004333 Phase II Study of the Enzyme Inhibitor NTBC for Tyrosinemia Type I Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004332 Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in Acromegaly Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004327 Phase II Pilot Study of Octreotide, a Somatostatin Octapeptide Analog, for Gastrointestinal Hemorrhage in Hormone-Refractory Hereditary Hemorrhagic Telangiectasia and Senile Ectasia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004305 Study of Genetic Anomalies of Complement Related Proteins in Patients With IgA Glomerulonephritis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004294 Phase I Study of Retrovirally Mediated Transfer of the Human Glucocerebrosidase Gene Into Peripheral Blood Stem Cells for Autologous Transplantation in Patients With Type I Gaucher Disease Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004293 Phase II Study of Glucocerebrosidase in Patients With Gaucher Disease Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004268 Phase II Study of Midodrine for Neurogenic Orthostatic Hypotension Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004266 Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004261 EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004260 Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004259 Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004258 EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004257 Oxaliplatin and Fluorouracil Plus Radiation Therapy in Treating Patients With Primary Esophageal or Stomach Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004256 Sargramostim to Prevent Mucositis in Patients Receiving Radiation Therapy for Laryngeal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004251 Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004250 Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004235 Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004234 Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004233 S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004232 Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004220 Oxaliplatin and Gemcitabine in Treating Patients With Advanced Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004218 Chemotherapy in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004205 Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004204 Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004203 Oxaliplatin in Treating Patients With Metastatic Bladder Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004202 Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004195 Eniluracil and Surgery in Treating Patients With Primary or Metastatic Colorectal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004194 Fludarabine in Treating Patients With Steroid-Resistant Chronic Graft- Versus-Host Disease Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004193 ISIS 2503 in Treating Patients With Metastatic and/or Locally Recurrent Colorectal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004192 Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004169 Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hodgkin's Disease Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004166 Amifostine in Treating Patients With Ovarian Epithelial Cancer Who Are Receiving Chemotherapy Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004161 Fenretinide in Treating Patients With Leukoplakia of the Mouth Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004160 Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004159 Gemcitabine Plus Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Solid Tumor Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004158 Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004157 Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004156 Vaccine Therapy in Treating Patients With Breast Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004151 Acridine Carboxamide in Treating Patients With Advanced Non-small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004150 High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004135 Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004132 Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004127 Oxaliplatin Combined With Fluorouracil and Leucovorin in Treating Patients With Recurrent or Metastatic Cancer of the Esophagus or Stomach Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004105 Combination Chemotherapy in Treating Patients With Advanced Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004104 Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004103 Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004102 Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004095 Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004094 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004093 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004092 Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004068 Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004067 Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004066 Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004061 Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004060 Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004059 Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004058 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004057 Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004056 Combination Chemotherapy Followed by Melphalan and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Acute Myeloid Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004051 Irinotecan in Treating Patients With Advanced Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004050 Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004033 Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004032 Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004005 Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004004 Procarbazine in Treating Patients With Recurrent Brain Tumor Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004003 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004002 PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003995 Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003994 Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003993 Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003992 Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003969 Geldanamycin Analogue in Treating Patients With Advanced Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003968 Bryostatin 1 in Treating Patients With Metastatic Kidney Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003967 Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003966 Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003961 Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic Syndrome Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003960 Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003959 Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003958 Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003957 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003956 Combination Chemotherapy in Treating Patients With Advanced Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003951 DX-8951f in Treating Patients With Metastatic Cancer of the Pancreas Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003950 Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003935 Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003934 Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003933 Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003920 Monoclonal Antibody Therapy Plus Cyclosporine and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003903 Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003902 Capecitabine and Vinorelbine in Treating Older Women Who Have Metastatic Breast Cancer With or Without Bone Involvement Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003895 Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003894 Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003893 Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003892 ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003869 Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003868 Radiolabeled Monoclonal Antibody, Cyclophosphamide, and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003867 Irinotecan and Capecitabine in Treating Patients With Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003861 Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003860 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003859 Surgery Plus Radiation Therapy With or Without Chemotherapy in Treating Children With Primitive Neuroectodermal Tumors of the CNS Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003858 Mitoxantrone Following Surgery in Treating Patients With Prostate Cancer at High Risk for Recurrence Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003857 Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003856 Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003851 Gemcitabine Compared With Pancreatic Enzyme Therapy Plus Specialized Diet (Gonzalez Regimen) in Treating Patients Who Have Stage II, Stage III, or Stage IV Pancreatic Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003850 Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003835 Combination Chemotherapy in Treating Patients With Stage III Colon Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003834 Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003833 Genetic Study in Patients With Stage II or Stage III Colon Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003832 Broxuridine Plus Surgery in Treating Patients With Stage I or Stage II Prostate Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003820 Rituximab in Treating Patients With Hodgkin's Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003805 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003804 Chemotherapy Plus Surgery in Treating Children at Risk of or With Stage I Wilms' Tumor Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003803 Chemotherapy Plus Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003802 Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003795 Quality of Life in Survivors of Gynecologic Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003794 Quality-of-Life Study of Patients With Previously Treated Ovarian Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003793 Genetic Study of Children With Soft Tissue Sarcoma or Rhabdomyosarcoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003792 Vaccine Therapy in Treating Patients With Metastatic Melanoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003769 Perillyl Alcohol Followed by Surgery in Treating Patients With Stage II or Stage III Pancreatic Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003768 Combretastatin A4 Phosphate in Treating Patients With Advanced Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003766 O6-benzylguanine Followed by Surgery in Treating Patients With Solid Tumors That Can Be Removed During Surgery Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003761 Vaccine Therapy in Treating Patients With Metastatic Breast Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003760 Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003759 AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003758 Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003757 Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine Therapy Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003751 Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003750 Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003735 Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003734 Combination Hormone Therapy Followed by Radiation Therapy in Treating Patients With Prostate Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003733 Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003732 Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003720 SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003718 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003705 BMS-184476 in Treating Patients With Advanced Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003704 Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003703 Chemotherapy in Treating Patients With Advanced Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003702 Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003695 Chemotherapy With or Without Surgery in Treating Patients With Stage II or Stage III Ovarian Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003694 Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003693 Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003692 Video-Assisted Surgery in Treating Patients With Non-small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003669 Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003667 Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003666 Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003661 Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003659 Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003658 Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003657 High-dose ICE With Amifostine Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003656 Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003650 Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003635 506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003634 Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003633 Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003632 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Central Nervous System Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003627 Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Advanced Cancer of the Oropharynx or Hypopharynx Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003620 Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003605 Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003604 Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer That Has Been Removed With Surgery Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003603 Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003602 Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003595 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003594 Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003593 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003592 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003569 Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003568 Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003567 Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003566 Thoracoscopy in Patients With Stage IIIA Non-Small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003561 Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003560 Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003558 Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003557 Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003556 Vaccine Therapy in Treating Patients With Melanoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003551 Aminocamptothecin in Treating Patients With Advanced or Recurrent Kidney Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003535 Antineoplaston Therapy in Treating Children With Recurrent or Refractory High-Grade Glioma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003534 Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003533 Antineoplaston Therapy in Treating Patients With Metastatic Prostate Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003532 Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003520 Antineoplaston Therapy in Treating Patients With Stage IV Kidney Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003518 Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003505 Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003502 Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003495 Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003494 Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003493 Combination Chemotherapy in Treating Patients With Multiple Myeloma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003492 Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00003469 Antineoplaston Therapy in Treating Children With Rhabdoid Tumor of the Central Nervous System Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View